Regenxbio
REGENXBIO Inc is an American clinical-stage biotechnology company focused on developing AAV-based gene therapy candidates for rare genetic and retinal diseases. The company utilizes its proprietary NAV Technology platform to engineer adeno-associated virus vectors for targeted therapeutic delivery. Principal revenue is derived from technology licensing royalties, commercial milestone payments, and collaborative research agreements with biopharmaceutical partners. Core end markets serve ophthalmology practices, pediatric neurology centers, and specialized rare disease clinical facilities globally. REGENXBIO holds a pioneer position in the biopharmaceutical industry as a foundational licensor of AAV gene delivery technologies. The company is headquartered in Rockville, Maryland, and its common stock trades on the Nasdaq Global Select Market.
3 of the funds FundTelligence covers report a position in Regenxbio.
- Legal name
- Regenxbio Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding Regenxbio
- JPM US Small Cap Growth Fund — JPM · 0.29 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)